Activist investors see Ackman-Valeant deal as a model to follow
April 22, 2014 at 18:32 PM EDT
NEW YORK, April 22 (Reuters) - William Ackman's $47 billion joint bid with Valeant Pharmaceuticals International Inc to buy Botox maker Allergan Inc may become a model for future deals, rival fund managers said.